{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/malaria-prophylaxis/how-this-topic-was-developed/evidence-exclusion-criteria/","result":{"pageContext":{"chapter":{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria","depth":2,"htmlHeader":"<!-- begin field c87024e2-26ed-4649-9490-a7f20188c08c --><h2>Evidence exclusion criteria</h2><!-- end field c87024e2-26ed-4649-9490-a7f20188c08c -->","summary":null,"htmlStringContent":"<!-- begin item 1d9ab3c9-8a31-4350-a789-a7f20187a3cf --><!-- begin field bd4fe521-6418-4c59-8337-a7f20188c08c --><h2>Our policy</h2><!-- end field bd4fe521-6418-4c59-8337-a7f20188c08c --><!-- begin field d895a9dc-27ca-4fb6-8c44-a7f20188c08c --><p>Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.</p><p>Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.</p><!-- end field d895a9dc-27ca-4fb6-8c44-a7f20188c08c --><!-- begin field 485d5c8a-eb5f-4014-b182-a7f20188c08c --><h2>Standard exclusions for scoping literature:</h2><!-- end field 485d5c8a-eb5f-4014-b182-a7f20188c08c --><!-- begin field bb3306fe-e80a-49ba-a036-a7f20188c08c --><ul><li>Animal studies</li><li>Original research is not written in English</li></ul><!-- end field bb3306fe-e80a-49ba-a036-a7f20188c08c --><!-- begin field c3d28b19-aa02-4290-89b7-a7f20188c08c --><h2>Possible exclusions for reviewed literature:</h2><!-- end field c3d28b19-aa02-4290-89b7-a7f20188c08c --><!-- begin field dc8a86d3-89e3-48d8-a975-a7f20188c08c --><ul><li>Sample size too small or study underpowered</li><li>Bias evident or promotional literature</li><li>Population not relevant</li><li>Intervention/treatment not relevant</li><li>Outcomes not relevant</li><li>Outcomes have no clear evidence of clinical effectiveness</li><li>Setting not relevant</li><li>Not relevant to UK</li><li>Incorrect study type</li><li>Review article</li><li>Duplicate reference</li></ul><!-- end field dc8a86d3-89e3-48d8-a975-a7f20188c08c --><!-- end item 1d9ab3c9-8a31-4350-a789-a7f20187a3cf -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","lastRevised":"Last revised in January 2018","chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","fullItemName":"Management","slug":"management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}